BPC-157 — body protection compound 157 — is one of the most heavily studied research peptides in the published preclinical literature, with hundreds of papers across rodent and in vitro models since the early 1990s. This article summarizes its structural identity, the conditions under which the molecule is stable, and the laboratory-handling factors that researchers cite as relevant to reproducible work. It is not a clinical guide and contains no dosing information.
Structural identity
- Sequence:
GEPPPGKPADDAGLV(15 amino acids) - Molecular formula: C₆₂H₉₈N₁₆O₂₂
- Average mass: 1419.55 g/mol
- Origin: A partial sequence derived from a larger gastric protein described by Sikiric and colleagues in the early 1990s. The peptide is synthetic; there is no biological extraction process.
The sequence contains no cysteines (so no disulfide-bond chemistry to manage), no methionines (so no oxidation-sensitive residues), and four prolines, which give it unusual conformational rigidity. The result is a peptide that is noticeably more stable to handling than many similarly sized compounds.
Published research scope
The body of published BPC-157 literature is overwhelmingly preclinical — cell culture work and rodent studies. Common experimental endpoints in the literature include:
- Wound-healing and connective-tissue models (Achilles tendon, ligament, skin) in rats.
- Gastrointestinal lesion models — the molecule was originally characterized in the context of gastric protection.
- Vascular and angiogenesis assays in vitro and in chick chorioallantoic membrane (CAM) preparations.
- Neurological and behavioral studies in rodent models, including encephalopathy and traumatic-injury paradigms.
As of 2026, controlled human clinical-trial data are extremely limited. Researchers planning work in this area should regard the molecule as preclinical and frame their experimental design accordingly.
Stability of lyophilized material
In the lyophilized state, BPC-157 is notably stable:
- Room temperature: Stable for transit (days to weeks) at typical shipping temperatures. Vendor-published shelf-life studies show minimal degradation by HPLC at ambient for short windows.
- 2–8°C (refrigerated): Manufacturer-stated shelf life of 24 months is typical for lyophilized vials stored sealed.
- −20°C (freezer): 36+ months for sealed, lyophilized vials in our internal stability data.
The absence of cysteine and methionine residues means BPC-157 is not particularly oxygen-sensitive, which is part of why it tolerates ambient conditions better than many peptides. Light protection is recommended but not as critical as it is for tryptophan-containing compounds.
Stability after reconstitution
Once dissolved in bacteriostatic water and refrigerated at 2–8°C, BPC-157 is generally considered stable for 28+ days. The benzyl alcohol in BAC water serves the bacteriostatic role; the peptide itself does not require acidification or special buffering at the concentrations typical for laboratory work.
Reconstitution recommendations from the broader peptide-research literature apply with no special exceptions for BPC-157:
- Stream the diluent against the glass wall, not the lyophilized cake.
- Swirl, do not shake.
- Refrigerate immediately after reconstitution. For working stocks held longer than ~30 days, aliquot and freeze at −20°C.
See our detailed reconstitution guide for the general protocol.
Salt forms and counter-ions
Most commercially available BPC-157 — including HelixCore's — is supplied as the trifluoroacetate (TFA) salt, which is the standard product of solid-phase peptide synthesis using TFA-based cleavage cocktails. The TFA counter-ion is removed for net peptide content calculations on the CoA. An acetate salt is occasionally requested for applications where TFA interference matters; it is available on special order but should not be assumed.
"Stable BPC-157" — sometimes marketed as a separate compound — refers to an arginate salt rather than a chemically distinct molecule. The peptide sequence is identical; only the counter-ion differs. Published comparative stability data between TFA and arginate forms in the laboratory setting are limited.
Common analytical and handling issues
Apparent "empty" vials
A 5 mg lot of BPC-157 lyophilizes into a thin, sometimes translucent film that can be difficult to see against the vial glass. Researchers occasionally report receiving "empty" vials and find that gentle tapping and reconstitution produce a normal, complete solution. The CoA's net peptide content is the source of truth for mass; visual estimation is unreliable.
Apparent solubility variation
BPC-157 dissolves readily in BAC water at the milligram-per-mL concentrations typical for research use. Reports of poor solubility almost always trace to one of three causes: insufficient swirl time, attempt to dissolve at concentrations above ~5 mg/mL (where viscosity and surface effects begin to matter), or use of an incorrect diluent.
Lot-to-lot purity drift
Modern solid-phase synthesis with HPLC purification routinely produces BPC-157 at >98% area-purity. Lower-purity material may show two specific patterns on RP-HPLC: a deletion-sequence peak (BPC-157 missing one glycine or proline residue, eluting close to the main peak) or a TFA-related early-elution peak that can be mistaken for an impurity but is in fact the counter-ion. The CoA chromatogram should distinguish these clearly. Read our CoA guide for the visual cues.
Where to find primary literature
PubMed indexes the bulk of BPC-157 preclinical work; search terms "BPC-157", "body protection compound 157", and "PL 14736" (the development designation used in some older papers) cover most of it. The Sikiric group at the University of Zagreb has published the largest single body of work and is a reasonable entry point.
Researchers planning experiments should approach this body of literature critically: a substantial portion is from a small number of collaborating groups, and independent replication outside these networks is more limited than the total paper count suggests.
